ATTR Cardiomyopathy Treatment Market

The global ATTR cardiomyopathy treatment market accounted for USD 1.71 billion in 2023 and is expected to reach USD 20.10 billion by 2034 with a CAGR of 25.11% during the forecast period 2024-2034. Rising Diagnosis Rates and Awareness, an aging population, the development of new therapies, and strategic collaborations and partnerships will all fuel market growth.

Improvements in diagnostic procedures such as cardiac imaging (echocardiography, cardiac MRI), genetic testing, and biomarker discovery enable earlier and more accurate detection of ATTR cardiomyopathy, highlighting the need for effective treatments. For instance, in February 2021, Pfizer Inc., a multinational pharmaceutical firm, announced a partnership with countrywide community organizations in the U.S. to promote awareness about ATTR-CM.

By type, the hereditary transthyretin amyloidosis segment accounted for the highest revenue-grossing segment in the global ATTR cardiomyopathy treatment market in 2023 owing to the significant prevalence of genetic mutations associated with this form of the disease and the increasing adoption of genetic testing for early diagnosis and personalized treatment approaches. For instance, in 2022, Pfizer reported positive Phase 3 findings for tafamidis in patients with ATTR cardiomyopathy. Additionally, the wild-type transthyretin amyloidosis segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing recognition of wild-type ATTR amyloidosis as a distinct clinical entity, advancements in diagnostic methods, and increasing awareness among healthcare professionals about the condition's prevalence in aging populations.

By drug type, the transthyretin stabilizers segment accounted for the highest revenue-grossing segment in the global ATTR cardiomyopathy treatment market in 2023 owing to the growing adoption of Tafamidis and other transthyretin stabilizers as first-line therapies due to their ability to slow disease progression and improve patient outcomes. For instance, in 2023, GlaxoSmithKline plc reported positive Phase 2 findings for GSK2398852 in familial ATTR amyloidosis. Additionally, the RNAi therapy segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing interest in RNAi therapies like Patisiran and Inotersen for their potential to directly target the underlying genetic cause of ATTR cardiomyopathy, leading to improved treatment outcomes and expanded patient access.

By distribution channel, the hospital pharmacies segment accounted for the highest revenue-grossing segment in the global ATTR cardiomyopathy treatment market in 2023 owing to the increasing prevalence of ATTR cardiomyopathy cases diagnosed and treated in hospital settings, coupled with the availability of specialized cardiac care facilities and comprehensive treatment options. For instance, in 2023, Prothena announced the start of a Phase 1b clinical trial of PRX004 in individuals with ATTR cardiomyopathy. Additionally, the online pharmacies segment is predicted to grow at the fastest CAGR during the forecast period owing to the growing adoption of online platforms for medication procurement, increased convenience, expanded geographic reach, and rising demand for home delivery services, especially among patients with chronic conditions like ATTR cardiomyopathy.

North American region is anticipated to have the highest revenue share during the forecast period owing to the region's robust healthcare infrastructure, high prevalence of ATTR cardiomyopathy cases, early adoption of advanced treatment modalities, supportive reimbursement policies, and significant investments in research and development initiatives. Additionally, the Asia Pacific region is predicted to grow at the fastest CAGR during the forecast period owing to the region's expanding geriatric population, increasing awareness about ATTR cardiomyopathy, improving healthcare infrastructure, rising healthcare expenditure, and growing focus on developing novel treatment options tailored to regional needs. For instance, in 2023, Alnylam reported good interim Phase 3 findings for patisiran in patients with ATTR amyloidosis.

This extensive research report concentrates on the size and projections of the global and regional markets from 2023 to 2034.

Report Scope:

• Base Year: 2023
• Forecast Period: 2024-2034
• Study Coverage
• Market Forecast by Type, Drug Type, and Distribution Channel
• Market Forecast for 5 Regions and 17+ Countries
• North America (U.S. and Canada)
• Europe (Germany, France, UK, Spain, Italy, Russia, Rest of Europe)
• Asia Pacific (China, Japan, India, Australia, South Korea, Rest of APAC)
• Latin America (Brazil, Mexico, Argentina, Rest of LATAM)
• MEA (South Africa, GCC, Rest of MEA)
• Exhaustive Company Profiles of the Top 10+ Major Market Players

Segmentation: ATTR Cardiomyopathy Treatment Market Report 2023 - 2034

ATTR Cardiomyopathy Treatment Market Analysis & Forecast by Type 2023 - 2034 (Revenue USD Bn)

• Hereditary Transthyretin Amyloidosis (hATTR)
• Wild Type Transthyretin Amyloidosis (wtATTR)

ATTR Cardiomyopathy Treatment Market Analysis & Forecast by Drug Type 2023 - 2034 (Revenue USD Bn)

• Transthyretin Stabilizers
• Nonsteroidal Anti-Inflammatory Drugs (NSAID)
• RNAI Therapy
• Others

ATTR Cardiomyopathy Treatment Market Analysis & Forecast by Distribution Channel 2023 - 2034 (Revenue USD Bn)

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

ATTR Cardiomyopathy Treatment Market Analysis & Forecast by Region 2023 - 2034 (Revenue USD Bn)

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• UK
• Spain
• Italy
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of APAC
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of LATAM
• Middle East & Africa
• South Africa
• GCC
• Rest of MEA